Korea recognizes ginseng for bone health
The Korean Ministry of Food and Drug Safety recently released a statement saying that ginseng was previously recognized for its ability to help improve immune system health and relieve fatigue. Currently, ginseng can claim 3 health claims in Korea: improving immune health, relieving fatigue, and improving bone health.
As a functional ingredient for improving bone health, ginseng extract contains 25 mg of ginsenoside Rg1 and Rb1 complex. The claim was released after research was presented on ginseng's ability to improve bone health. The 12-week study, led by the Korea Rural Development Agency (RDA), will continue to investigate new functions of ginseng while supporting its use on an industrial scale.
Ginseng, which has a relatively low value compared to red ginseng, would greatly boost ginseng consumption if it were developed into a variety of functional health foods. This is in line with Korea's overall strategy to promote the export of domestically produced functional health foods, of which ginseng is one.
2026-09-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Enhance the National Cultural Soft Power to Promote Chinese Food Culture going out
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
FSANZ Moves Toward Approval of Insect-Resistant Corn COR121
-
Thymol Gel Wins EPA Approval for Beekeepers
-
FDA Tightens the Solvent Side of Natural Color Production
-
India’s Tariff Cuts Could Lower Agrochemical Costs
-
FDA Slams Door on Chinese Food Exports: Inspection Refusals Trigger Automatic Detentions
-
US Tariff Pressure on Canada Raises Risks for North American Chemical Supply Chains
-
FDA Slows Two Natural Color Approvals, but the Additive Shift Is Still Moving
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
Recommend Reading
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
Four Fine Chemical Units of Huajin Aramco Project – HDPE, EO/EG, etc. – Reach Mechanical Completion
-
WACKER’s 2025 Loss Reaches €805 Million as the PACE Cost-Cutting Plan Becomes the Key Variable for 2026
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
Business Society’s PC Market Outlook on September 3, 2026: Volatile
-
This week, the Chinese propylene oxide market showed a downward trend from a high position (8.10-8.12)
-
This Week's Pure Benzene Market Prices Rise in China (8.31-9.4)
-
Business Society’s PTA Market Outlook on August 13, 2026: Volatile
-
This Week's Styrene Market Rises Sharply (8.31-9.4) in China